Medical Specialty >> Gynecology
Study Counters Myth That Contraceptive Pill Enlarges Breasts in Teen Girls
10:31 AM CDT.
Read article
- 1 in 5 Young Women Has No Plans to Get a Mammogram
- More Evidence COVID Vaccination Can Cause Temporary Change in Menstrual Cycle
- Researchers May Have Noninvasive Way to Diagnose Endometriosis
- Abuse Early in Life May Mean Tougher Menopause Decades Later
JOURNAL UPDATE
Male Physicians Receive More and Higher Payments From Medical Companies
4:08 PM CDT.Wider compensation gap between male and female physicians seen in 2019 versus 2013
- COVID-19 Pandemic Tied to Burnout in Health Care Professionals
- Acetaminophen Exposure in Utero Tied to Child Neurobehavioral Problems
- Breast Cancer Incidence Slowly Increased in Recent Years
MONTHLY JOURNAL SUMMARY
September 2020 Briefing - OBGYN & Women’s Health
October 01, 2020. The Monthly Journal Summary is a single article covering the most important journal articles published in the previous 30 days.
FEATURED ARTICLES
Immunotherapy with Checkpoint Inhibitors in Triple Negative Breast Cancer (TNBC)
Karima Oualla, MD.
Dr. Karima Oualla discusses recent advances on the use of checkpoint inhibitors in the treatment of triple negative breast cancer (TNBC). Dr. Oualla is an International expert in breast cancer and is the primary author of the manuscript entitled "Novel therapeutic strategies in the treatment of triple-negative…
Rucaparib Maintenance Therapy Improves PFS in Platinum-sensitive Ovarian Cancer - The ARIEL3 Trial
Robert L. Coleman, MD.
Professor Robert L. Coleman M.D., FACOG, FACS discusses the implications of data from the Phase 3 ARIEL3 trial of the novel PARP inhibitor rucaparib as maintenance therapy in patients with platinum-sensitive ovarian cancer. Professor Coleman is the Vice Chair of Clinical Research in the Department of…
Characterization of patients with ovarian carcinoma who respond to the PARP inhibitor rucaparib
Elizabeth M. Swisher, MD.
Dr. Elizabeth M. Swisher comments on the implications of new data from the ARIEL2 trial, an ongoing Phase 2 trial of the novel PARP inhibitor rucaparib in relapsed, high-grade serous or endometrioid ovarian cancer. The new results offer an important insight into the genetic mechanisms behind tumor sensitivity…
MEDICAL FOCUS
Breast cancer
By Tamer M. Fouad, M.D. Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer is the second most common type of cancer after lung cancer (11.9%…
DISCUSSION
RE: Investigational Topical Minocycline Gel for Acne Advances to Phase III Development
By namabcAs I understand, this is a great step of development that we can use to save many people from horrible diseases. and i also hope Dr.Lain and your partners…
